5 days ago
2
JHVEPhoto/iStock Editorial via Getty Images
Sanofi (NASDAQ:SNY) ADRs fell ~10% in the premarket on Thursday after data from a late-stage trial for amlitelimab, its experimental therapy for the inflammatory skin condition atopic dermatitis (often referred to as eczema), disappointed investors.
The French drugmaker said that
English (US) ·